You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
|
|---|---|
| Published in |
Molecular Cancer, December 2012
|
| DOI | 10.1186/1476-4598-11-91 |
| Pubmed ID | |
| Authors |
Andrea Cavazzoni, Roberta R Alfieri, Daniele Cretella, Francesca Saccani, Luca Ampollini, Maricla Galetti, Federico Quaini, Gallia Graiani, Denise Madeddu, Paola Mozzoni, Elena Galvani, Silvia La Monica, Mara Bonelli, Claudia Fumarola, Antonio Mutti, Paolo Carbognani, Marcello Tiseo, Elisabetta Barocelli, Pier Giorgio Petronini, Andrea Ardizzoni |
| Abstract |
The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HER-targeting by monoclonal antibodies such as cetuximab and trastuzumab or tyrosine-kinase inhibitors as gefitinib or erlotinib has been proven effective in the treatment of advanced NSCLC. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | 2% |
| Greece | 1 | 2% |
| Italy | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 39 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 28% |
| Student > Ph. D. Student | 7 | 16% |
| Student > Bachelor | 4 | 9% |
| Professor | 4 | 9% |
| Student > Master | 4 | 9% |
| Other | 6 | 14% |
| Unknown | 6 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 35% |
| Agricultural and Biological Sciences | 9 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Veterinary Science and Veterinary Medicine | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 8 | 19% |